Gazyvaro 1,000 mg concentrate for solution for infusion. clinical trials
3 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study
This study, called UPROOT, is looking into a new treatment for Sjögren's syndrome using a medicine called Gazyvaro. It aims to see if Gazyvaro can reduce certain immune cells in the blood and affected areas, which might help improve symptoms of Sjögren's syndrome.
For: Sjögren's syndromeNetherlands - AuthorisedTherapeutic exploratory (Phase II)
Obinutuzumab induced decreases of PLA2Rab in MN: a pilot study
This study is looking at a new treatment called Gazyvaro (obinutuzumab) for a kidney disease called primary membranous nephropathy. It aims to see how well the medicine reduces certain antibodies (PLA2R antibodies) that cause the disease, and if it helps improve kidney function and quality of life.
For: Primary membranous nephropathyNetherlands - AuthorisedTherapeutic exploratory (Phase II)
Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)
This clinical trial looks at whether a medicine called obinutuzumab can help adults with lupus that affects their kidneys. Researchers want to see if this treatment can reduce kidney swelling, improve kidney health over one year, and allow people to cut down on their daily steroid tablets.
For: systemic lupus erythematosus pure membranous nephropathyFrance